These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15124496)

  • 1. [Biovigilance. (Decree no 2003-1206 of December 12, 2003].
    Villeneuve P
    Rev Infirm; 2004 Mar; (99):39-40. PubMed ID: 15124496
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of declarations of severe adverse effects from the publication of the decree dated 13 March 1995 about the organisation of pharmacovigilance].
    Lelouet H; Morin M; Trenque T; Bidault I; Castot A; Alexandre JM
    Therapie; 1996; 51(5):555-6. PubMed ID: 9138393
    [No Abstract]   [Full Text] [Related]  

  • 3. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 4. [Events and adverse reactions in biovigilance: Descriptive analysis of French national data following a four-year practical experience].
    Martinière K; Lucas S; Zorzi P
    Transfus Clin Biol; 2008 Sep; 15(4):179-89. PubMed ID: 18538607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The nurse and public health surveillance].
    Chevillotte J; Venchiarutti L
    Rev Infirm; 2008 Sep; (143):29-31. PubMed ID: 18788665
    [No Abstract]   [Full Text] [Related]  

  • 6. [Reporting drug side effects in dermatology].
    Jonville-Béra AP
    Ann Dermatol Venereol; 2001 Jan; 128(1):58. PubMed ID: 11291643
    [No Abstract]   [Full Text] [Related]  

  • 7. [Requirements for long-term follow-up on efficacy and safety of advanced therapy medicinal products. Risk management and traceability].
    Klug B; Reinhardt J; Schröder C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):58-62. PubMed ID: 19949763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 9. US creates blame-free adverse event reporting.
    Guthrie P
    CMAJ; 2006 Jan; 174(1):19-20. PubMed ID: 16389225
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug induced injury and informed consent.
    O'Grady J; Isitt V
    Med Leg J; 2001; 69(Pt 2):96-100. PubMed ID: 11447718
    [No Abstract]   [Full Text] [Related]  

  • 11. Coxibs, science, and the public trust.
    Solomon DH; Avorn J
    Arch Intern Med; 2005 Jan; 165(2):158-60. PubMed ID: 15668360
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunization in France: high quality regulation].
    Fuchs F
    Arch Pediatr; 2006 Jun; 13(6):648-50. PubMed ID: 16697585
    [No Abstract]   [Full Text] [Related]  

  • 13. Canada proposes amendments to adverse drug reaction reporting.
    McMahon E; Reguly T
    Health Law Can; 2009 Oct; 30(1):9. PubMed ID: 19994551
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 15. [Research into the risk of malignancy from biologicals: utility of meta-analysis hampered].
    Vermeer NS; De Bruin ML
    Ned Tijdschr Geneeskd; 2013; 157(6):A5884. PubMed ID: 23388143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Medical Products Agency is responsible for the control of medical technological products: we need more active medical professionals reporting shortages].
    Philipson L
    Lakartidningen; 2008 Mar 5-11; 105(10):746-7. PubMed ID: 18422241
    [No Abstract]   [Full Text] [Related]  

  • 17. Vioxx, radiology, and the Food and Drug Administration.
    Pentecost MJ
    J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841
    [No Abstract]   [Full Text] [Related]  

  • 18. [Interview -- drug legislation -- reporting unexpected adverse drug reactions].
    Ludwig WD
    Pneumologie; 2009 Sep; 63(9):479-80. PubMed ID: 19764017
    [No Abstract]   [Full Text] [Related]  

  • 19. [Materials monitoring].
    Fumagalli B
    Soins Chir; 1997 Dec; (186):5-6. PubMed ID: 9479224
    [No Abstract]   [Full Text] [Related]  

  • 20. [Monitoring cosmetic product safety].
    Vigan M
    Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S55-8. PubMed ID: 17563716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.